Dasatinib (Sprycel) is a second-generation tyrosine kinase inhibitor that plays a crucial role in the treatment of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
What Are the Side Effects of Dasatinib (Sprycel)?
Common Side Effects
Hematological toxicity: Myelosuppression (neutropenia, thrombocytopenia, anemia).
Fluid retention events: Pleural effusion, peripheral edema, pulmonary edema.
Gastrointestinal reactions: Diarrhea (22%), nausea (10%).
Neurological symptoms: Headache (14%).
Skin reactions: Rash (14%).
Other common reactions: Bleeding events, dyspnea, fatigue, musculoskeletal pain.
Severe Adverse Reactions Requiring High Alert for Dasatinib (Sprycel)
Myelosuppression Crisis
Severe (Grade 3/4) thrombocytopenia, neutropenia, and anemia may occur.
Monitoring requirements: For adults with chronic-phase CML, complete blood count (CBC) should be tested every 2 weeks in the first 12 weeks, and then every 3 months thereafter. Patients with advanced-phase CML or Ph+ ALL need weekly testing until 2 months.
Increased Bleeding Risk
Dasatinib may cause severe or even life-threatening bleeding events.
In clinical studies, the incidence of Grade ≥3 central nervous system (CNS) bleeding was <1%, but bleeding at any site requires immediate medical intervention.
Pulmonary Arterial Hypertension (PAH)
It may occur at any time after the start of treatment (including more than 1 year later).
Typical symptoms: Dyspnea, fatigue, hypoxia, fluid retention.
Management principle: Permanent discontinuation of the drug is required once diagnosed.
Precautions for Using Dasatinib (Sprycel)
Administration Specifications
Swallow the tablets whole; do not crush, split, or chew them.
It can be taken with food or on an empty stomach.
Administer the drug at a fixed time every day.
Management of Drug Interactions
Strong CYP3A4 inhibitors (e.g., ketoconazole): Dose reduction should be considered.
Strong CYP3A4 inducers (e.g., rifampicin): Dose increase may be required.
Gastric acid regulators: Avoid concurrent use with H2-receptor antagonists or proton pump inhibitors.
Treatment Monitoring Specifications
Hematological monitoring: Regularly test the complete blood count.
Biochemical indicator monitoring: Test liver function monthly.
Cardiac monitoring: Regularly evaluate the electrocardiogram (ECG) and cardiac function.
